protein
| secreted protein, acidic, cysteine-rich (osteonectin), SPARC (Termine et al, 1981) |
|
von Willebrand factor, VWF (Pareti et al, 1986) |
|
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor), ITGA2 (Staatz et al, 1990) |
|
biglycan, BGN (Schönherr et al, 1995) |
|
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase), MMP9 (Mäkelä et al, 1998) |
|
Nidogen-2, NID2 (Kohfeldt et al, 1998) |
|
platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog), PDGFB (Shimizu et al, 1999) |
|
metalloproteinase-2, MMP-2 (Ellerbroek et al, 2001) |
|
Matrilin-2, MATN2 (Piecha et al, 2002) |
|
Thioredoxin, TRX (Matsumoto et al, 2002) |
|
NFKB is a strong inhibitor of collagen synthesis and of COL1A1 transcription in healthy and scleroderma fibroblasts, and RELA subunit of NFKB being responsible for the inhibitory action |
|
COL1A1 and ITM2A genes both regulate the expressions of calcium channel genes |
| mice expressing a partially deleted COL1A1 gene have bones significantly shorter in length, a decrease in wet weight, mineral content and collagen content (Pereira et al, 1993) | |
mouse Aga2, with a dominant frameshift mutation in the Col1a1 C-propeptide domain, have OI phenotypic changes and endoplasmatic reticulum (ER) stress-related apoptosis in bone tissue |
|
mice expressing a mutated COL1A1 gene exhibit phenotypic variability and incomplete penetrance of Osteogenesis imperfecta (Pereira et al, 1994) |
|
transgenic mice with a targeted mutation in COL1A1 gene display ocular hypertension (Aihara et al, 2003) |